Nektar outlines $400M–$460M year-end 2026 cash target as REZPEG enters Phase III in atopic dermatitis
Nektar Therapeutics · PHARMACEUTICAL PREPARATIONS · Now $63.86
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS